Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Nektar Therapeutics NKTR
$0.72
-$0.02 (-2.29%)
На 18:00, 12 мая 2023
+2 226.39%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
136968299.00000000
-
week52high
5.18
-
week52low
0.60
-
Revenue
92055000
-
P/E TTM
0
-
Beta
1.08961900
-
EPS
-2.04000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| JP Morgan | Underweight | Neutral | 08 авг 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 18 апр 2022 г. |
| Mizuho | Neutral | Neutral | 18 апр 2022 г. |
| Goldman Sachs | Sell | Neutral | 18 апр 2022 г. |
| Canaccord Genuity | Buy | Buy | 16 мар 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Zalevsky Jonathan | D | 313663 | 13460 | 16 ноя 2022 г. |
| ROBIN HOWARD W | D | 979793 | 38014 | 16 ноя 2022 г. |
| Thomsen Jillian B. | D | 323764 | 11095 | 16 ноя 2022 г. |
| Wilson Mark Andrew | D | 272498 | 8690 | 16 ноя 2022 г. |
| Curet Myriam | D | 31777 | 4198 | 23 сент 2022 г. |
| Ajer Jeffrey Robert | D | 38512 | 4198 | 23 сент 2022 г. |
| CHESS ROBERT | D | 228179 | 5100 | 22 сент 2022 г. |
| WHITFIELD ROY A | A | 20400 | 20400 | 16 сент 2022 г. |
| WHITFIELD ROY A | A | 246250 | 10200 | 16 сент 2022 г. |
| EASTHAM KARIN | A | 20400 | 20400 | 16 сент 2022 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 5004020 | -35702 | 31 авг 2020 г. |
| iShares Core S&P Mid-Cap ETF | 4718060 | -10020 | 31 авг 2020 г. |
| Invesco Oppenheimer Global Opportunities Fund | 32523000 | 0 | 31 июл 2020 г. |
| Vanguard Small-Cap Index Fund | 4424430 | -34123 | 31 июл 2020 г. |
| Fidelity Growth Company Fund | 3769270 | -25812 | 31 июл 2020 г. |
| First Trust NYSE Arca Biotechnology Index Fund | 3172630 | -179351 | 31 июл 2020 г. |
| Vanguard Small-Cap Growth Index Fund | 2692640 | -14286 | 31 июл 2020 г. |
| Vanguard Health Care Fund | 13392600 | 0 | 30 июн 2020 г. |
| PRIMECAP Odyssey Aggressive Growth Fund | 11377200 | -61160 | 30 июн 2020 г. |
| PRIMECAP Odyssey Growth Fund | 6502960 | -859102 | 30 июн 2020 г. |
Новостная лента
Nektar Therapeutics (NKTR) Q1 2023 Earnings Call Transcript
Seeking Alpha
09 мая 2023 г. в 22:14
Nektar Therapeutics (NASDAQ:NKTR ) Q1 2023 Earnings Conference Call May 9, 2023 5:00 PM ET Company Participants Vivian Wu - Investor Relations Howard Robin - President and Chief Executive Officer Jonathan Zalevsky - Chief, Research and Development Mary Tagliaferri - Chief Medical Officer Sandra Gardiner - Acting Chief Financial Officer Conference Call Participants Jerry Gong - Mizuho Daina Graybosch - SVB Securities Operator Good day and thank you for standing by. Welcome to the Nektar Therapeutics First Quarter 2023 Financial Results Conference Call.
Forget Bargain Hunting, Buy 5 Stocks With Rising P/E
Zacks Investment Research
18 апр 2023 г. в 08:24
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Disney (DIS), Casey's General Stores (CASY), OpGen (OPGN), Accelerate Diagnostics (AXDX) and Nektar Therapeutics (NKTR).
Nektar stock pops as more than half of San Francisco office loses jobs, new CFO appointed
Market Watch
17 апр 2023 г. в 17:54
Nektar Therapeutics shares rallied late Monday after the biotech drug maker said it was cutting staff by 60% in San Francisco, where the company is based, and shifting its focus to immunology drugs in a partnership with Eli Lilly & Co. LLY, -0.64%. Nektar shares popped as much as 7% in the extended session, after they closed the regular session up 6.3% at 98 cents a share.
7 Sorry Pharma Stocks to Sell in April Before It's Too Late
InvestorPlace
16 апр 2023 г. в 06:30
Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing in pharma stocks can also mean heavy expenditures on research and testing for a drug that may not perform as well as scientists hope.
Here's Why You May Add Nektar (NKTR) Stock to Your Portfolio
Zacks Investment Research
13 апр 2023 г. в 12:10
Here we discuss some reasons why investing in Nektar Therapeutics (NKTR) stock now is a good idea despite its several pipeline setbacks.